Oxford BioDynamics Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OXBOF research report →
Price Chart
About the company
Headquartered in Oxford, United Kingdom, and established in 2007, Oxford BioDynamics Plc operates as a biotechnology enterprise. The company's primary focus lies in the discovery and development of biomarkers for the pharmaceutical and biotechnology industries, serving both domestic and international markets, with a significant presence in the United States. Central to its operations is EpiSwitch, a proprietary technology platform.
- CEO
- Richard Compton
- IPO
- 2020
- Employees
- 51
- HQ
- Oxford, OXF, GB
Get TickerSpark's AI analysis on OXBOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.20M
- P/E
- -0.31
- PEG
- -0.00
- P/S
- 2.23
- P/B
- 1.46
- EV/EBITDA
- -0.50
- Div Yield
- 0.00%
- Gross Margin
- -277.32%
- Op Margin
- -792.72%
- Net Margin
- -825.61%
- ROE
- -451.74%
- ROIC
- -114.20%
Latest fiscal year · YoY change
- Revenue
- $1.09M+72.2%
- Gross Profit
- $522.00K+80.6%
- Op Income
- $-11,074,000
- Net Income
- $-11,153,000+3.6%
- EPS
- $-0.01+82.2%
- OCF Growth
- +25.6%
- FCF Growth
- +27.4%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.15
- RSI (14)
- 8
- Avg Volume
- 5.93K
No earnings-call transcripts are available for OXBOF yet.
- Free Float
- 65.0%
- Shares Outstanding
- 2.13B
- Float Shares
- 1.39B
Our OXBOF coverage
Recent articles, reports, and earnings notes.
No research on OXBOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OXBOF report →Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome
proactiveinvestors.co.uk · Oct 8
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy
proactiveinvestors.co.uk · Oct 8
Oxford BioDynamics shares climb blood test findings
proactiveinvestors.co.uk · Sep 4
Oxford BioDynamics partners with Google Cloud - ICYMI
proactiveinvestors.co.uk · Aug 22
Oxford BioDynamics soars on new Google collab
proactiveinvestors.co.uk · Aug 13
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
proactiveinvestors.co.uk · Jul 15
Oxford BioDynamics shares jump on UK lab accreditation for flagship cancer test
proactiveinvestors.co.uk · May 9
Oxford BioDynamics slumps on warning of need for new funding
proactiveinvestors.co.uk · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.